HCM · HUTCHMED (China) Ltd
$12.20
+0.04 (+0.33%)
At close · Aug 14
Market Cap
$2.12B
Shares
173.81M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.20
Open$12.19
Day$12.08–12.27
52W close$9.99–17.93
Avg vol 30d44K
Short int181K · 0.1% float · 3.8d
Short vol53%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Up next
Next earnings call
Jan 29, 2027
Est · unconfirmed
· in 24 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
+10%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
28%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+13%
trailing
6-month return
−20%
trailing
YTD return
−8%
this year
Relative strength
−33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $13 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.10% of float · ▼ -6.9% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
56 holders — mid 3-yr range
Squeeze score
44
elevated · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+1200%
Y/Y
Free cash flow
$-78.8M
Balance sheet
$21.8M
net debt
Quant / Vol
risk profile
Volatility
35%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
2.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2025
2026
Oncology revenue
$330M – $450M
the next few years
R&D investment
$250M – $300M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
+10%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
28%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $13 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.10% of float · ▼ -6.9% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
56 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $10
Now $12 · 28%
Range high $18
vs 200-day avg -9%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HCM
this stock
HUTCHMED (China) Ltd
|
$2.12B | -8.5% | +19.7% | — | 0.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.49B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HCM | -2.5% | +12.6% | -19.6% | +9.6% | -8.5% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.9% | +8.1% | -33.4% | +5.7% | -22.3% |
Key facts
CIK
1648257
CUSIP
44842L103
13F (30d)
55 filings
55 filers
Visit website
Investor relations